EvrysdiActive Ingredient(s): Risdiplam
FDA Approved: * August 7, 2020
Pharm Company: * GENENTECH INC
Category: Genetic Disorders
Risdiplam, sold under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy (SMA) and the first oral medication approved to treat this disease. Risdiplam is a survival of motor neuron 2-directed RNA splicing modifier. In clinical trials, the most common adverse events included fever, diarrhea, rash, ulcers of the mouth area, joint pain (a... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.